Evidence map›Paper›PMID 40115713›Full record

ArticleCureus2025

Neurofeedback for COVID-19 Brain Fog: A Secondary Analysis.

JeAnnah Rose AbouAssaly, Tatsuya Masuko, Harue Sasai-Masuko, Frederick Strale

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

JeAnnah Rose AbouAssalyNeurofeedback, The Oxford Center, Brighton, USA.
Tatsuya MasukoOrthopedic Surgery, Emerald Orthopedic & Pain Clinic, Sapporo, JPN.
Harue Sasai-MasukoInternal Medicine, Emerald Orthopedic & Pain Clinic, Sapporo, JPN.
Frederick StraleBiostatistics, The Oxford Center, Brighton, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This secondary analysis technical report uses quantitative electroencephalography (qEEG) neurofeedback to treat brain fog, a group of cognitive challenges such as sluggish thinking, memory lapses, confusion, and poor focus, often observed in long COVID. In the original case report, a 34-year-old female patient was administered approximately 15 sessions of Z-score neurofeedback. Pretest and post-test neurofeedback training qEEG reported significant declines in high-beta activity, i.e., beta, Hi beta, beta 1, and beta 3, and notable increases in alpha and theta brainwaves. These improvements were most evident at electrode sites C4, F3, and P3. The patient reported improved attention and memory, reduced anxiety, and less pain, although depression reduction was less. These results suggest that a relatively short program of neurofeedback can assist in shifting the brain from hyperarousal to a calmer, more efficient state. This may potentially offer a non-pharmacological method for treating constant post-COVID brain fog. Additional studies are necessary to validate these findings.

Indexed as

brain fogcovid-19mild-to-severe cognitive dysfunctionneurofeedback therapyquantitative eeg (qeeg)z-score neurofeedback

Identifiers

PMID40115713
PMCPMC11925212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.